Preclinical Viral Vector Vaccine Development

Viral vector vaccines are a type of vaccine that uses a harmless virus to deliver a gene from a disease-causing virus or bacteria into human cells. This gene instructs the cells to produce a protein that will trigger an immune response against the disease-causing virus or bacteria. Viral vector vaccines are safe, effective, and induce long-lasting immunity. Many viral vectors are being tested against a vast array of viruses. In addition, many viral vector platforms are currently used in gene and cell therapy. Viral vectors offer great versatility and can be custom tailored. Approved viral vector vaccines include the Ebola vaccine and SARS-CoV-2 vaccine.


Accelerate Your Vaccine Development with Southern Research

Southern Research is a leading contract research organization (CRO) that specializes in the preclinical development of viral vector vaccines. We have a team of experienced scientists and researchers who are experts in all aspects of viral vector vaccine development, including:

      • Design, construction, expression, and purification of viral vector vaccine candidates
      • In vitro and in vivo testing of viral vector vaccine candidates
      • Assessment of the safety and efficacy of viral vector vaccine candidates in animals models
      • Consulting on the development and scale-up of a manufacturing process for viral vector vaccine candidate

We offer a wide range of preclinical viral vector vaccine development services, including:

      • Feasibility studies: We can help you assess the feasibility of developing a viral vector vaccine for your target disease.
      • Lead optimization: We can help you optimize your viral vector vaccine candidate to improve its safety and efficacy.
      • Preclinical testing: We can conduct all of the necessary preclinical testing to evaluate the safety and efficacy of your viral vector vaccine candidate in animal models.
      • Manufacturing development: We can help you develop a manufacturing process for your viral vector vaccine candidate so that it can be produced at scale for clinical trials.

If you are developing a viral vector vaccine candidate, we encourage you to contact us to learn more about how we can help you accelerate your vaccine development.